Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-based differences in long-term mortality after TAVR among patients with bicuspid aortic valve.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Fate of dilated ascending aorta after transcatheter aortic valve replacement.

JTCVS structural and endovascular·2026
Same author

On-Scene, Residential Extracorporeal Cardiopulmonary Resuscitation for Refractory Out-of-Hospital Cardiac Arrest: Operational and Logistical Considerations.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Hemodynamic-guided V-A ECMO management for cardiogenic shock: Insight from initial experience from TWEET study (to wean an ECMO trials).

Perfusion·2026
Same author

Left Ventricular Venting Strategies for Cardiogenic Shock in Patients Treated With Extracorporeal Cardiopulmonary Support V-A ECMO: From Left Ventricular Unloading to Offloading.

The American journal of cardiology·2026
Same author

Detection of progression of asymptomatic severe aortic stenosis using Apple Watch-estimated maximal oxygen consumption (VO<sub>2</sub> max): a case report.

European heart journal. Case reports·2026

Related Experiment Video

Updated: Jul 4, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Devices for heart failure: the future is now.

Harvinder Singh Arora1, Pranav Loyalka, Biswajit Kar

  • 1Cardiopulmonary Transplant Service of the Texas Heart Institute, Houston, TX, USA.

Congestive Heart Failure (Greenwich, Conn.)
|June 14, 2008
PubMed
Summary

Despite advances in heart failure (HF) drugs, patient outcomes haven't improved. Cardiac assist devices offer a promising alternative for managing advanced HF and improving prognosis.

More Related Videos

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Pharmacologic therapies for heart failure (HF) have advanced significantly.
  • Despite these advances, epidemiological studies show no improvement in HF prognosis over 40 years.
  • Hospitalizations for acute decompensated HF are increasing, even with complex drug regimens.

Purpose of the Study:

  • To review the current applications of cardiac assist devices in managing heart failure.
  • To highlight recent technological advancements in cardiac assist devices.
  • To explore the potential of mechanical circulatory support in improving HF outcomes.

Main Methods:

  • Literature review of studies on cardiac assist devices for heart failure.
  • Analysis of current clinical practices and outcomes associated with these devices.
  • Synthesis of recent research on innovations in mechanical circulatory support.

Main Results:

  • Cardiac assist devices are increasingly utilized in various clinical settings for HF management.
  • These devices show promise in improving the quality of life and survival for advanced HF patients.
  • Ongoing research and development are yielding more sophisticated and effective cardiac assist technologies.

Conclusions:

  • Cardiac assist devices represent a critical therapeutic option for heart failure, complementing pharmacologic treatments.
  • Mechanical circulatory support is essential for managing advanced heart failure where medical therapy is insufficient.
  • Continued innovation in cardiac assist devices is crucial for addressing the unmet needs in heart failure care.